An observational study in Cytopenia and MDS, sponsored by Weizmann Institute of Science. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Weizmann Institute of Science · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Cytopenia with a site in United States — 17 open to participants now, 22 under way, 2 of them phase 3. Cytopenia · United States.
Among the 51 studies in Cytopenia with a site in United States, this one is one of 4 that started in 2025, is one of 5 observational ones, reaches primary completion later than 10 of the 20 other live ones, and was the 49th registered.
81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.
Browse Cytopenia studies →17 of the 51 studies in Cytopenia with a site in United States are open now. Recruiting first, the newest first:
Takeda · Sites in United States, Australia, Bulgaria and 12 more countries
Ages 18+
Takeda · Sites in United States, Australia, Bulgaria and 15 more countries
Ages 18+
Lachelle D. Weeks, MD, PhD · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
University of Southern California · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Cytopenia studies recruiting now, 17 (85%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 3
First in 1996; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 202 across 15 observational studies indexed under Cytopenia.
Median enrollment 33 across the 32 interventional studies, 1,500 across the 5 observational. Of the 28 that completed or were terminated, 6 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 51 have an industry lead sponsor. The 10 most frequent:
Weizmann Institute of Science is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
Weizmann Institute of Science has 1 study filed under Cytopenia — fewer than ten, so there is no comparison to draw.
3 of the studies in Cytopenia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02143830Children's Hospital Medical Center, CincinnatiHSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | 2026-12 |
| NCT06802146Lachelle D. Weeks, MD, PhDEarly Intervention in High Risk CCUS | 2026-12-01 |
| NCT04873102University of Southern CaliforniaDanazol for Treatment of Cytopenias in Patients With Cirrhosis | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Cytopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.
This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing. Current MDS diagnosis relies on bone marrow (BM) aspiration and biopsy, which is invasive, technically challenging, and sometimes inconclusive, particularly in early or low-risk disease. Our prior research established a healthy reference map of cHSPC subtypes and developed a computational pipeline that distinguishes MDS from non-clonal cytopenias based on deviations from this reference. In this study, patients referred, as part of standard care, for BM evaluation due to unexplained cytopenias or abnormal blood counts and undergo PB collection for genomic profiling. The study's primary objective is to develop a PB-based test by comparing the developed test diagnoses to the conventional BM-based one. Secondary objectives include evaluating its potential for MDS risk stratification and assessing its ability to reduce the need for BM evaluations.
Patients with cytopenia, who are referred to BM from the primary care clinic will be recruited to the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention is given
Diagnostic Test: PERIBLOOD-MDS
In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology
To develop PERIBLOOD-MDS diagnostic test of PB cHPCs for the diagnosis of MDS
Comparison between PERIBLOOD-MDS diagnosis and bone marrow evaluation of MDS
Time frame: Three months following the peripheral blood sample
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weizmann Institute of Science